United States Patent 10,765,667: scope of claims covering rifaximin 550 mg TID for 14 days in IBS patients ≥65 and its US patent landscape

US Patent 10,765,667 claims a specific clinical method for irritable bowel syndrome (IBS) in subjects aged 65 years or older, using rifaximin 550 mg three times daily (TID) for 14 days, with symptom-response measurement concepts. The claim set is tightly framed around (i) the age qualifier (≥65), (ii) dose regimen (550 mg TID x 14 days), and (iii) outcomes defined by baseline reductions or affirmative patient-reported responses, with dependent claims specifying IBS subtypes (diarrhea-predominant, alternating) and specific symptom clusters including bloating associated with IBS-D.

This claim structure creates enforceable coverage against US inducement/doctor-patient practice theories for the claimed regimen in the covered population, but it also narrows design-around options to changes in age restriction, dose/frequency/duration, indication framing, or response definition mechanics (e.g., different endpoints not captured by the claimed “affirmative response” or “after 7 days” constructs).

What does US Patent 10,765,667 claim for IBS in patients 65 and older?

Core independent claim (Claim 1) covers:

Patient population: “a subject 65 years of age or older”
Condition: “one or more symptoms of irritable bowel syndrome (IBS)”
Treatment: administering 550 mg rifaximin TID for 14 days
Outcome linkage: “thereby treating one or more symptoms”

Claim 1 scope boundaries

Formulation scope: not limited to a specific dosage form in the claim text you provided, but the regimen implies a rifaximin oral dose matching 550 mg strength. If the patent relies on a particular commercial strength or drug product form, that would narrow coverage in prosecution history not provided here.
Severity and baseline: Claim 1 does not require baseline measurement or specific endpoint definitions beyond “treating symptoms,” but dependent claims introduce those concepts.
Symptom scope: dependent claims define symptom categories; Claim 1 is broader as written (“one or more symptoms”).

How broad is the symptom coverage in claim 1 versus dependent claims?

Dependent claim 2: defined IBS symptom list

Claim 2 narrows Claim 1 by specifying symptoms selected from:

cramping, pain
diarrhea, constipation
lumpy stool, watery stool
frequent stool production
abdominal pain, abdominal discomfort
urgency

Practical implication: This list maps onto typical IBS symptom diary and patient-reported clusters. Enforceability risk is higher where clinical practice documents improvement in one or more of these listed symptoms in the ≥65 population after the claimed rifaximin regimen.

IBS subtype dependents: claims 3 and 4

Claim 3: IBS is diarrhea-predominant (IBS-D)
Claim 4: IBS is alternating IBS

Practical implication: These add additional indication-like qualifiers. Even if Claim 1 covers “one or more symptoms of IBS,” the subtype dependents strengthen coverage for specific IBS market segments (IBS-D and alternating IBS) where prescribers may treat consistent symptom patterns.

What treatment-response definitions are claimed (baseline reduction and “affirmative response”)?

Two dependent claim themes define outcomes:

Baseline reduction endpoint (Claims 5-6)

Claim 5: reduction from baseline symptoms established prior to treatment
Claim 6: reduction achieved following 7 days after administration

Scope effect:

“Baseline” plus “following 7 days” can be used to distinguish from regimens measured only at end-of-therapy or later follow-ups.
It may also support arguments that a clinician’s documentation method or clinical trial protocol falls within the claim even if the overall clinical course is longer.

Affirmative response endpoint (Claims 7, 10, 11, 16)

Claim 7: reduction corresponds to an affirmative response from the subject when asked whether they had a reduction in symptoms of IBS.

Similarly, for bloating:

Claim 10: reduction achieved following 7 days
Claim 11: affirmative response when asked about reduction in bloating

And:

Claim 16: affirmative response when asked about reduction in bloating

Scope effect:

“Affirmative response” is a method-of-assessing efficacy. That can capture real-world practice if the physician uses a similar question/response structure documented as patient affirmative report.
It is also a design-around target if a sponsor uses different question formats, different scales, or different measurement frameworks not falling within “affirmative response” as interpreted by the patent.

What separate claim coverage exists for bloating associated with IBS-D?

Independent Claim 8 (bloating associated with diarrhea-predominant IBS)

Claim 8 is an independent method claim that covers:

Population: subject 65 years old or older
Condition: “bloating associated with diarrhea-predominant IBS”
Treatment: 550 mg rifaximin TID for 14 days
Outcome: treating bloating

Dependent structure for bloating (Claims 9-16)

Claim 9: treating bloating comprises reduction of bloating
Claim 10: reduction achieved after 7 days
Claim 11: reduction defined by affirmative response when asked about reduction in bloating
Claim 12: adds treating additional diarrhea-predominant symptoms selected from the same expanded symptom list plus tenesmus
Claims 13-15: baseline comparison and “following 7 days” for reduction
Claim 16: affirmative response for reduction in bloating

Notable addition:

Tenesmus is included only in the bloating-dependent add-on symptom list (Claim 12).

How does the claim set constrain design-around strategies for generic rifaximin?

The claims are method claims. For third parties seeking to compete with rifaximin in the US, design-around is most practical by changing at least one required element:

Age qualifier: avoid prescribing the claimed method for a population limited to “≥65” (hard in practice because clinicians can treat individuals across age ranges).
Dose regimen: avoid 550 mg TID for 14 days. Any labeled regimen or clinical practice using different dosing and duration may reduce risk.
Condition framing: the claim requires “IBS symptoms” and, in certain dependents, IBS-D or alternating IBS, and for bloating claims specifically “bloating associated with IBS-D.”
Efficacy endpoint mechanics:
- “baseline established prior to treatment”
- “reduction achieved following 7 days”
- “affirmative response” when asked

Method patents can still be asserted even if a product is the same, because inducement or direct infringement can depend on how the method is practiced, not just what drug is dispensed.

What is the patent landscape around rifaximin in IBS in the US (and how does this claim likely fit)?

Rifaximin has an extensive US patent history in IBS, typically covering:

polymorphs/formulations (less likely for this particular method claim text),
use and dosing regimens for IBS indications,
and population or endpoint-specific claims (like age or measurement timing).

Given the claim language, 10,765,667 is positioned as an adult/subpopulation-specific dosing-and-outcome method patent rather than a chemistry/formulation patent.

Landscape mapping by claim elements (functional taxonomy)

Drug: rifaximin at 550 mg
Regimen: TID x 14 days
Population modifier: ≥65
Disease framing: IBS symptoms; dependent on IBS-D and alternating IBS
Outcome: early timepoint 7 days and patient-reported “affirmative response,” plus baseline reduction.

This combination is characteristic of later-expiring or continuation-driven claims aimed at capturing commercial use after initial foundational dosing/exposure patents.

Which prior art and earlier patents are most likely implicated in validity challenges?

While you supplied only the claim text and not the file history, the claim scope points to obvious validity attack surfaces that are typical in US method-of-use/indication patents:

Potential obviousness/nonobviousness themes

Whether treating IBS with rifaximin 550 mg TID for 14 days was already disclosed for IBS generally.
Whether a ≥65 subpopulation was recognized with a rationale to apply the same regimen (e.g., safety/tolerability/efficacy subgrouping).
Whether “early response” timing at 7 days was already described in earlier clinical endpoints.
Whether “affirmative response” question-based endpoints were known in IBS symptom trials.

Potential anticipation themes

Single references that already disclose: (i) rifaximin 550 mg TID x 14 days, (ii) IBS symptom improvement endpoints, (iii) patient-age subset ≥65, and/or (iv) question/affirmative response measurement timing.

These are factual/legal determinations tied to the specific cited references in the prosecution and the actual disclosure wording.

What patent risks exist for generic market entry tied to these claims?

Because the claim requires how a clinician treats, generic entrants face risk through:

Induced infringement via labeling or promotion that encourages the claimed regimen for the covered population.
Direct infringement by physicians if they practice the method as claimed in the US.
Paragraph IV litigation exposure (where such method claims are listed in the Orange Book for a rifaximin NDA).

The key for risk severity in practice is whether 10,765,667 is listed in the Orange Book for a relevant rifaximin product/NDA and whether generic applicants would carve out the claimed use in labeling. Without Orange Book listing data in your input, the risk ranking cannot be completed with the level of precision required for decision-making.

What does this mean for licensing strategy and settlement posture?

Method patents with tight elements (age + dose + endpoint mechanics) often support:

license offers focused on specific patient subsets and labeling language,
NDA paragraph IV settlements that include “skinny label” restrictions or compliance commitments for certain regimens/endpoints,
or carve-outs where the generic agrees not to market or instruct the claimed method in the US.

If 10,765,667 is asserted in a litigation posture, the settlement leverage typically comes from:

clarity of claim elements (easy for a court to compare practice),
ability to show infringement via trial protocol documentation and patient age criteria,
and whether the NDA label references the specific regimen and targeted endpoints.

How strong is the patent estate for rifaximin IBS regimens, based on claim drafting patterns?

10,765,667 itself is strong in enforceability terms because it has:

a single, concrete regimen (550 mg TID for 14 days),
a clear population limit (≥65),
symptom and outcome definitions that make claim-to-practice mapping relatively direct.

Its weakness, typical for such claims, is that it depends on practice of the full combination. Competitors can sometimes reduce risk by changing at least one claim element. Still, because clinicians treat individual patients and follow standard IBS regimens, the remaining design-around space may be narrow.

Claim chart style breakdown of infringement elements (practical mapping)

For Claim 1 (IBS symptoms, ≥65, rifaximin 550 mg TID x 14 days)

A practitioner’s method practice would need:

subject is ≥65
treating IBS symptoms
administering rifaximin 550 mg TID
for 14 days
thereby treating one or more IBS symptoms

For Claim 6 (baseline reduction after 7 days)

Add:

baseline symptom assessment prior to treatment
symptom reduction “achieved following 7 days after administration”

For Claim 7 (affirmative response)